Literature DB >> 30217570

Role of the endocannabinoid system in drug addiction.

Jorge Manzanares1, David Cabañero2, Nagore Puente3, María S García-Gutiérrez4, Pedro Grandes5, Rafael Maldonado6.   

Abstract

Drug addiction is a chronic relapsing disorder that produces a dramaticglobal health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  CB1 receptors; CB2 receptors; CB2R allosteric modulators; Mesolimbic system; Nucleus accumbens; Prefrontal cortex; Rimonabant

Mesh:

Substances:

Year:  2018        PMID: 30217570     DOI: 10.1016/j.bcp.2018.09.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  30 in total

1.  Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.

Authors:  Zheng-Xiong Xi; Pretal Muldoon; Xiao-Fei Wang; Guo-Hua Bi; M Imad Damaj; Aron H Lichtman; Roger G Pertwee; Eliot L Gardner
Journal:  Br J Pharmacol       Date:  2019-10-28       Impact factor: 8.739

2.  Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms.

Authors:  Ewa Galaj; Guo-Hua Bi; Hong-Ju Yang; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-08-19       Impact factor: 5.250

Review 3.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 4.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

5.  Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice.

Authors:  Hai-Ying Zhang; Hui Shen; Ming Gao; Zegang Ma; Briana J Hempel; Guo-Hua Bi; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2021-03-28       Impact factor: 5.250

6.  Beta-caryophyllene inhibits cocaine  addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use disorder.

Authors:  Ewa Galaj; Guo-Hua Bi; Allamar Moore; Kai Chen; Yi He; Eliot Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2020-10-17       Impact factor: 7.853

7.  Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice.

Authors:  Hai-Ying Zhang; Lindsay De Biase; Ramesh Chandra; Hui Shen; Qing-Rong Liu; Eliot Gardner; Mary Kay Lobo; Zheng-Xiong Xi
Journal:  Acta Pharmacol Sin       Date:  2021-07-27       Impact factor: 6.150

Review 8.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

9.  β-Caryophyllene, a dietary terpenoid, inhibits nicotine taking and nicotine seeking in rodents.

Authors:  Yi He; Ewa Galaj; Guo-Hua Bi; Xiao-Fei Wang; Eliot Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 9.473

10.  CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking.

Authors:  Russell S Dulman; Huaibo Zhang; Ritabrata Banerjee; Harish R Krishnan; Bin Dong; Basalingappa L Hungund; K Yaragudri Vinod; Subhash C Pandey
Journal:  Neuropharmacology       Date:  2021-05-26       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.